Powering Rare Disease Access with Real-World Evidence

10

June

  • 3pm London 10am New York
  • Free
  • Why attend?
  • Speakers
  • Contact Us

Why attend?

Speakers

Select a speaker to learn more

Back
Dr. Raymond A. Huml
Vice President of Rare & Orphan Disease Strategy

Dr. Raymond A. Huml is the Vice President of Rare & Orphan Disease Strategy at Sciensus, with over 30 years in the healthcare and biopharmaceutical industries. A leader in rare disease research and global due diligence, he has driven nearly $3 billion in capital commitments. A prolific author and award-winning expert, he is dedicated to advancing rare disease innovation, diversity, and global healthcare, including his Peace Corps service in Ghana.

  • With over 30 years in the healthcare and biopharmaceutical industries
  • Has driven nearly $3 billion in capital commitments
  • Prolific author and award-winning expert
Next speaker
Back
Alastair MacDonald
Vice President, Medical Affairs

Alastair has 30+ years of experience in the biopharmaceutical development of pre and post approval drugs.

From 2001-2017, Alastair held a variety of senior positions at AstraZeneca, including as Global Head of Delivery for RWE. Here, he had responsibility for the delivery of both pre and post approval evidence generation programs supporting key assets that have gone on to become world-class products.

From 2017-2024, he worked at Syneos Health, a world-leading Product Development Organisation. As a Senior Vice President of Strategic Alliances, he assisted key clients to clinically develop and successfully commercialise assets, particularly through the generation of RWE.

Now Vice President, Medical Affairs at Sciensus, Alastair successfully helps patients across Europe gain access to treatments and candidate drugs. Enabled by this primary source patient access, data is captured through an innovative digital platform. These real-world insights drive better health outcomes including adherence and patient engagement.

Next speaker

Enquiry